Trial reportBritish journal of clinical pharmacology2018
Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
Trial report in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01835197 (A Phase 1, Within Cohort, Randomized, Double Blind, Third-Party Open, Placebo-Controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-04965842 In Healthy Western and Japanese Subjects), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, Within Cohort, Randomized, Double Blind, Third-Party Open, Placebo-Controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-04965842 In Healthy Western and Japanese Subjects
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of LW402, a preferential Janus kinase 1 inhibitor in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial.Frontiers in pharmacology · 2026Trial
- Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.British journal of clinical pharmacology · 2018Trial
- Application of Machine Learning and Mechanistic Modeling to Predict Intravenous Pharmacokinetic Profiles in Humans.Journal of medicinal chemistry · 2025Article
- Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.European journal of drug metabolism and pharmacokinetics · 2024Article
- New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.Pharmaceutics · 2024Review
- Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis.Pharmaceutics · 2023Review
- Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers.Clinical pharmacology in drug development · 2022Article
- Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial.Dermatology and therapy · 2022Article
- Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis.Dermatology and therapy · 2022Review
- Recent insights into the management of treatment-resistant pediatric atopic dermatitis.International journal of women's dermatology · 2022Review
- Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.European journal of drug metabolism and pharmacokinetics · 2022Article
- Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis.Clinical pharmacokinetics · 2022Article
- Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.Journal of clinical pharmacology · 2022Article
- Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase Ⅰ study.Frontiers in pharmacology · 2022Article
- Abrocitinib: First Approval.Drugs · 2021Review
- Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.Journal of clinical pharmacology · 2021Article
- The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data.Drug design, development and therapy · 2021Review
- Article
- Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis.ImmunoTargets and therapy · 2020Review
- New and Emerging Therapies for Pediatric Atopic Dermatitis.Paediatric drugs · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo determine the safety, tolerability, pharmacokinetics and pharmacodynamics of the Janus kinase 1-selective inhibitor, PF-04965842.
methodsThis was a phase 1, first-in-human, randomized, double-blind, placebo-controlled, combination single- and multiple-dose escalation, parallel design study in healthy subjects (http://clinicaltrials.gov, NCT01835197). Subjects received a single dose of placebo or 3, 10, 30, 100, 200, 400 or 800 mg PF-04965842 (single ascending dose phase) and placebo or 30 mg once daily (QD), 100 mg QD, 200 mg QD, 400 mg QD, 100 mg twice daily (BID) or 200 mg BID PF-04965842 for 10 consecutive days (multiple ascending dose phase). The primary objective was to determine the safety and tolerability of PF-04965842.
resultsSeventy-nine subjects were randomized and received study treatments. There were no deaths or serious adverse events. The most frequent treatment-emergent adverse events were headache (n = 13), diarrhoea (n = 11) and nausea (n = 11). PF-04965842 was absorbed rapidly (median time at which maximum plasma concentration occurred generally ≤1 h following either single- or multiple-dose administration) and eliminated rapidly (mean t
conclusionsThese results support further evaluation of PF-04965842 for clinical use in patients with inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.